Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc. is demonstrating an attractive current valuation, as indicated by a recent net present value (NPV) analysis that suggests substantial upside potential from the current share price. The company is focused on developing cannabinoid-based formulations, with investigational drug assets like IGC-AD1 showing encouraging preclinical results in targeting key hallmarks of Alzheimer's disease. Additionally, the anticipation of further positive data and advancements in their drug development pipeline is expected to act as a catalyst for the stock's upward momentum.

Bears say

IGC Pharma Inc reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(0.02), which aligns with previous estimates but indicates ongoing financial challenges. The company faces several significant risks, including balance sheet liquidity concerns, potential failures of its investigational drugs in clinical trials, and hurdles related to regulatory approvals and commercialization. Additionally, external factors such as competition and shifting investor sentiment toward biotech stocks further contribute to the negative outlook for IGC Pharma's financial health and stock performance.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Feb 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.